Zanubrutinib (Zanu) vs Bendamustine + Rituximab (BR) in Patients (Pts) With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Extended Follow-Up of the SEQUOIA Study

Abstract P639

Talha Munir,[1*] Mazyar Shadman,[2*] Tadeusz Robak,[3] Jennifer R. Brown,[4] Brad S. Kahl,[5] Paolo Ghia,[6] Krzysztof Giannopoulos,[7,8] Martin Šimkovič,[9] Anders Österborg,[10] Luca Laurenti,[11] Patricia Walker,[12] Stephen Opat,[13] Hanna Ciepluch,[14] Richard Greil,[15,16] Merit Hanna,[17] Monica Tani,[18] Marek Trněný,[19] Danielle M. Brander,[20] Ian W. Flinn,[21] Sebastian Grosicki,[22] Emma Verner,[23,24] Alessandra Tedeschi,[25] Sophie De Guibert,[26] Gayane Tumyan,[27] Kamel Laribi,[28] José A. García-Marco,[29] Jian-Yong Li,[30] Tian Tian,[31] Vanitha Ramakrishnan,[31] Yu Liu,[31] Andy Szeto,[31] Jason Paik,[31] Aileen Cohen,[31] Constantine S. Tam,[32**] Wojciech Jurczak[33**]

[1]Haematology, Haematological Malignancy Diagnostic Service (HMDS), St James's Institute of Oncology, Leeds, UK; [2]Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA; [3]Medical University of Lodz, Lodz, Poland; [4]Dana-Farber Cancer Institute, Boston, MA, USA; [5]Washington University School of Medicine, St Louis, MO, USA; [6]Strategic Research Program on Chronic Lymphocytic Leukemia, Division of Experimental Oncology, IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy; [7]Experimental Hematooncology Department, Medical University of Lublin, Lublin, Poland; [8]Hematology Department, St John's Cancer Centre, Lublin, Poland; [9]University Hospital Hradec Králové, Hradec Králové, Czech Republic; [10]Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden; [11]Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; [12]Peninsula Health and Peninsula Private Hospital, Frankston, Melbourne, VIC, Australia; [13]Monash Health and Clinical Haematology Unit, Monash University, Clayton, VIC, Australia; [14]Department of Hematology, Copernicus Regional Oncology Centre, Gdansk, Poland; [15]Third Medical Department with Hematology, Medical Oncology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria; [16]Salzburg Cancer Research Institute Center for Clinical Cancer and Immunology Trials, Salzburg, Austria; [17]Department of Haematology, Waitemata District Health Board, Takapuna, New Zealand; [18]Hematology Unit, Santa Maria delle Croci Hospital, Ravenna, Italy; [19]First Department of Medicine, First Faculty of Medicine, Charles University, General Hospital, Prague, Czech Republic; [20]Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC, USA; [21]Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA; [22]Department of Hematology and Cancer Prevention, School of Public Health, Medical University of Silesia, Katowice, Poland; [23]Concord Repatriation General Hospital, Concord, NSW, Australia; [24]University of Sydney, Sydney, NSW, Australia; [25]Department of Hematology, Azienda Socio Sanitaria Territoriali Grande Ospedale Metropolitano Niguarda, Milan, Italy; [26]Hôpital Pontchaillou, Rennes, France; [27]Department of Chemotherapy of Hemoblastosis, Blokhin Russian Cancer Research Center, Moscow, Russia; [28]Hematology Department, Centre Hospitalier du Mans, Le Mans, France; [29]Laboratorio de Citometria de Flujo, Servicio de Hematologia y Hemoterapia, Hospital Universitario de Getafe, Getafe, Madrid, Spain; [30]Department of Hematology, Jiangsu Province Hospital, Nanjing, China; [31]BeiGene USA, San Mateo, CA, USA; [32]Alfred Health and Monash University, Melbourne, VIC, Australia; [33]Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland

* Equal contribution; ** Co-senior authors

BACKGROUND

- BTK inhibitors have transformed the therapeutic landscape for CLL/SLL by demonstrating prolonged PFS and OS over chemoimmunotherapy, the traditional standard of care[1]
- Zanubrutinib, a next-generation BTK inhibitor designed to minimize off-target binding and limit associated side effects,[2] is approved in the US,[3] EU,[4] and China[5] for CLL/SLL
- Results from the SEQUOIA study (NCT03336333), at a median follow-up of 26.2 months, demonstrated superior PFS in treatment-naive patients with CLL/SLL without del(17p) who received zanubrutinib vs BR (HR, 0.42; 95% CI, 0.28-0.63; 2-sided *P*<.0001); results were similar in treatment-naive patients with del(17p) who received zanubrutinib monotherapy[6]
- An independent data monitoring committee determined that the SEQUOIA study met its primary endpoint at the interim analysis[6]
- Here, we report the updated efficacy and safety results from the SEQUOIA study after approximately 18 months of additional follow-up (data cutoff: 31 October 2022)

METHODS

- Methodological details have been published[6] and are summarized in **Figure 1**

Figure 1. Study Design



C, cycle; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; CRi, CR with incomplete hematologic recovery; FCR, fludarabine, cyclophosphamide, rituximab; FISH, fluorescence in situ hybridization; IGHV, immunoglobulin heavy variable; INV, investigator; iwCLL, International Workshop on Chronic Lymphocytic Leukemia; pt, patient.
* Defined as Cumulative Illness Rating Scale >6, creatinine clearance <70 mL/min, or a history of previous severe infection or multiple infections within the last 2 years. ᵃ One patient without del(17p) was misassigned to the nonrandomly assigned cohort of patients with del(17p). The patient is excluded from the efficacy analysis in this cohort. ᵇ Defined as the time from randomization to death or the date of progression on the next line of therapy subsequent to study treatment.

RESULTS

Patients

- As of 31 October 2022, 479 patients without del(17p) had been randomized to receive zanubrutinib (n=241) or BR (n=238), and 111 patients with del(17p) received zanubrutinib monotherapy; 180 patients (74.7%) without del(17p) and 78 patients (70.3%) with del(17p) were still receiving zanubrutinib
- The median follow-up was 43.7 months (range, 0-60.0 months) in cohort 1 and 47.9 months (range, 5.0-56.9 months) in cohort 2
- In arm B, 188 patients (79.0%) completed their BR regimen, 86 (36.1%) had progression irrespective of completing the full 6 cycles, and 41 (17.2%) crossed over to receive zanubrutinib after centrally confirmed disease progression
- Zanubrutinib discontinuation rates in patients without and with del(17p) were 24.9% and 29.7%, respectively
- Baseline demographics and disease characteristics were similar across treatment groups (**Table 1**)

Table 1. Patient Characteristics and Baseline Demographics

	Patients without del(17p)		Patients with del(17p)
	Arm A: zanubrutinib (n=241)	Arm B: BR (n=238)	Arm C: zanubrutinib (n=111)ᵃ
Age, median (range), years	70 (40-86)	70 (35-87)	71 (42-87)
Age ≥65 years, n (%)ᵇ	198 (82)	195 (82)	95 (86)
Male, n (%)	154 (64)	144 (61)	79 (71)
ECOG PS 2, n (%)	15 (6)	20 (8)	14 (13)
Geographic region, n (%)			
North America	34 (14)	28 (12)	12 (11)
Europe	174 (72)	172 (72)	52 (47)
Asia-Pacific	33 (14)	38 (16)	47 (42)
Binet stage C, n (%)ᶜ	70 (29)	70 (29)	39 (35)
Bulky disease ≥5 cm, n (%)	69 (29)	73 (31)	44 (40)
Cytopenia at baseline, n (%)ᵈ	102 (42)	110 (46)	61 (55)
Unmutated IGHV, n/N (%)ᵉ	125/234 (53)	121/231 (52)	67/103 (65)
del(11q), n (%)	43 (18)	46 (19)	37 (33)
***TP53* mutation, n/N (%)**	15/232 (6)	13/223 (6)	47/109 (43)
Complex karyotype with ≥3 abnormalities, n/N (%)ᶠ	23/164 (14)	22/161 (14)	33/88 (38)

BR, bendamustine plus rituximab; CLL, chronic lymphocytic leukemia; ECOG PS, Eastern Cooperative Oncology Group performance status; IGHV, immunoglobulin heavy variable; SLL, small lymphocytic lymphoma.
ᵃ One patient without del(17p) was misassigned to the nonrandomly assigned cohort of patients with del(17p). The patient is excluded from the efficacy analysis in this cohort; ᵇ Patients aged ≥75 years included 63 patients in group A (26%), 53 patients in group B (22%), and 27 patients in group C (24%). ᶜ Patients with SLL had Binet stage calculated as if they had CLL; ᵈ Defined as having anemia (hemoglobin <110 g/L), thrombocytopenia (platelets <100×10⁹/L), or neutropenia (absolute neutrophil count ≤1.5×10⁹/L). ᵉ Twenty-two patients had insufficient RNA quantity/quality for polymerase chain reaction amplification of immunoglobulin heavy chain variable region for sequencing or had missing data; ᶠ Patients with missing/insufficient metaphase activity were omitted from the complex karyotype analysis.

Efficacy

- In cohort 1, median PFS was not reached in patients who received zanubrutinib; in patients who received BR, median PFS was 42.2 months (**Figure 2A**)
  - Estimated 42-month PFS rates with zanubrutinib and BR were 82.4% and 50.0%, respectively
- PFS was significantly improved with zanubrutinib vs BR in patients with mutated IGHV (2-sided *P*=.00033) and unmutated IGHV (2-sided *P*<.0001) (**Figure 2B**)
- CR/CR with incomplete hematologic recovery (CRi) rates in patients without del(17p) who received zanubrutinib vs BR were 17.4% vs 21.8%, respectively
- Median OS was not reached in either group; the estimated 42-month OS rates were 89.4% and 88.3%, respectively (**Figure 2C**)
- In cohort 2, the median PFS and OS were not reached; the estimated 42-month rates were 79.4% and 89.5%, respectively (**Figure 2D**), and the CR/CRi rate was 14.5%

Figure 2. PFS and OS in Cohort 1 [Without del(17p)] and Cohort 2 [With del(17p)][a]



BR, bendamustine plus rituximab; IGHV, immunoglobulin heavy variable; m, median; NE, not evaluable; zanu, zanubrutinib.
ᵃ All *P* values are 2-sided.

Safety

- AEs of interest (AEIs) in patients without del(17p) receiving zanubrutinib vs BR and in patients with del(17p) are shown in **Table 2**
- Exposure-adjusted incidence rates for hypertension were similar between arms and lower than previously reported (**Table 3**)

Table 2. Treatment-Emergent and Posttreatment AEIs[a] in Cohorts 1 and 2 (Any Grade and Grade ≥3)[b]

	Patients without del(17p)				Patients with del(17p)	
	Arm A: zanubrutinib (n=240)ᵃ		Arm B: BR (n=227)ᵇ		Arm C: zanubrutinib (n=111)	
AEIs, n (%)	**Any grade**	**Grade ≥3**	**Any grade**	**Grade ≥3**	**Any grade**	**Grade ≥3**
Infections	175 (72.9)	57 (23.8)	142 (62.6)	50 (22.0)	89 (80.2)	30 (27.0)
Bleeding	117 (48.8)	14 (5.8)	28 (12.3)	4 (1.8)	64 (57.7)	6 (5.4)
Other malignancies	45 (18.8)	22 (9.2)	28 (12.3)	11 (4.8)	27 (24.3)	8 (7.2)
Hypertension	42 (17.5)	22 (9.2)	31 (13.7)	15 (6.6)	15 (13.5)	7 (6.3)
Diarrhea	41 (17.1)	4 (1.7)	32 (14.1)	5 (2.2)	22 (19.8)	1 (0.9)
Neutropenia	40 (16.7)	30 (12.5)	129 (56.8)	116 (51.1)	21 (18.9)	18 (16.2)
Arthralgia	37 (15.4)	2 (0.8)	23 (10.1)	1 (0.4)	26 (23.4)	1 (0.9)
Anemia	17 (7.1)	1 (0.4)	47 (20.7)	5 (2.2)	7 (6.3)	0 (0)
Thrombocytopenia	15 (6.3)	5 (2.1)	41 (18.1)	18 (7.9)	9 (8.1)	2 (1.8)
Atrial fibrillation/flutter	12 (5.0)	3 (1.3)	6 (2.6)	3 (1.3)	7 (6.3)	5 (4.5)
Myalgia	9 (3.8)	0 (0)	4 (1.8)	0 (0)	8 (7.2)	1 (0.9)
Opportunistic infection	6 (2.5)	1 (0.4)	4 (1.8)	3 (1.3)	1 (0.9)	1 (0.9)

AEI, AE of interest; BR, bendamustine plus rituximab.
ᵃ Patients who did not receive zanubrutinib are not included in the safety analysis; ᵇ Patients who did not receive BR are not included in the safety analysis.

Table 3. Summary of EAIRs[a] for Select AEIs

	Patients without del(17p)		Patients with del(17p)
	Arm A: zanubrutinib (n=240)ᵇ	Arm B: BR (n=227)ᶜ	Arm C: zanubrutinib (n=111)
Atrial fibrillation and flutter	0.13	0.08	0.15
Hemorrhage	2.02	0.40	2.73
Major hemorrhage	0.20	0.05	0.20
Hypertension	0.49	0.45	0.35

AEI, AE of interest; BR, bendamustine plus rituximab; EAIR, exposure-adjusted incidence rate.
ᵃ EAIR was calculated as the number of patients with an event in each TEAE category divided by the total time from the first dose date to the first event date, or the exposure time if no event occurred; ᵇ Patients who did not receive zanubrutinib are not included in the safety analysis; ᶜ Patients who did not receive BR are not included in the safety analysis.

CONCLUSIONS

- The extended follow-up in the SEQUOIA study showed that the efficacy of zanubrutinib was maintained in previously untreated patients with CLL/SLL without del(17p) and that PFS rates were similar in patients with and without del(17p); OS rates were high in all arms of the trial
- Additionally, patients with mutated IGHV who received zanubrutinib demonstrated significant improvements in PFS with extended follow-up vs those who received BR; patients with unmutated IGHV who received zanubrutinib maintained the PFS benefit vs patients who received BR that was observed at the interim analysis
- Zanubrutinib was well tolerated over this extended treatment period and aligned with the known profile of BTK inhibitors; atrial fibrillation events remained low
- The results of this extended follow-up in the SEQUOIA study support the use of zanubrutinib as a valuable first-line treatment option for elderly patients with CLL/SLL and those with del(17p)

REFERENCES

1. Scheffold A, Stilgenbauer S. *Curr Oncol Rep*. 2020;22(2):16.
2. Guo Y, et al. *J Med Chem*. 2019;62(17):7923-7940.
3. Brukinsa (zanubrutinib). Package insert. BeiGene USA; 2023. Available at https://beigene.com/news/beigene-receives-new-approvals-for-brukinsa-zanubrutinib-in-china/1e5cd979-7835-4263-8dde-1426c72ffb3e/. Accessed May 22, 2023.
4. Brukinsa (zanubrutinib). Summary of product characteristics. BeiGene Ireland Ltd; 2021.
5. BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China; 2023. Available at https://beigene.com/news/beigene-receives-new-approvals-for-brukinsa-zanubrutinib-in-china/1e5cd979-7835-4263-8dde-1426c72ffb3e/. Accessed May 22, 2023.
6. Tam CS, et al. *Lancet Oncol*. 2022;23(8):1031-1043.

DISCLOSURES

TM: Honoraria: Janssen, AbbVie, Gilead, Alexion, Novartis, Roche; Consulting role: MorphoSys, Sunesis. **MS:** Consulting fees: AbbVie, Genentech, AstraZeneca, Sound Biologics, Pharmacyclics, BeiGene, Bristol Myers Squibb, MorphoSys/Incyte, TG Therapeutics, Innate Pharma, Kite Pharma, Adaptive Biotechnologies, Epizyme, Eli Lilly, Adaptimmune, Mustang Bio, Regeneron, Merck, Fate therapeutics, MEI pharma, Atara Biotherapeutics; Research funding: Mustang Bio, Celgene, Bristol Myers Squibb, Pharmacyclics, Gilead, Genentech, AbbVie, TG Therapeutics, BeiGene, AstraZeneca, Sunesis, Atara Biotherapeutics, Genmab, MorphoSys/Xencor, Viracor. **TB:** Research funding: BeiGene, Octapharma, AstraZeneca, Janssen, Regeneron, GSK; Honoraria: AstraZeneca, BeiGene, Janssen, AbbVie, Octapharma, Regeneron, GSK; Travel, accommodations, expenses: AstraZeneca. **JB:** Consulting fees: AbbVie, AcertaAstraZeneca, BeiGene, Bristol-Myers Squibb/Juno/Celgene, Catapult, Eli Lilly, Genentech/Roche, Janssen, MEI Pharma, Pfizer, Pharmacyclics; Research funding: BeiGene, Gilead, iOnctura, Loxo/Lilly, MEI Pharma, Securobio, Sun, TG Therapeutics. **BK:** Research funding: BeiGene to Washington University School of Medicine (St Louis, MO, USA); Consulting fees: AbbVie, AstraZeneca, BeiGene, Janssen, Pharmacyclics. **PG:** Honoraria: AbbVie, AstraZeneca, BeiGene, Janssen, LillyLoxo, MEI, Roche, Sanofi; Research funding: AbbVie, AstraZeneca, Janssen, Sunesis. **KG:** Consulting fees: BeiGene; Funding: AbbVie, Amgen, AstraZeneca, Janssen, Novartis, Roche, Sanofi-Genzyme, Takeda and paid to the Next Generation Hematology Association; Consulting fees: GSK, Sandoz; Honoraria: AbbVie, Amgen, AstraZeneca, BeiGene, Gilead, GSK, Janssen, Karyopharm, Novartis, Pfizer, Roche, Sandoz, Takeda, Teva; Travel, accommodations, expenses: Janssen, Roche, Sanofi-Genzyme; Advisory Board: AbbVie, Amgen, AstraZeneca, Gilead, GSK, Janssen, Novartis, Roche, Sandoz, Takeda; Leadership role: the Next Generation Hematology Association. **MS:** Consulting fees: AbbVie, AstraZeneca, Janssen-Cilag; Individual stocks: AbbVie, AstraZeneca, Johnson & Johnson, BeiGene, Gilead, Baxter, Novartis, Abbot, Sanofi; Honoraria: AbbVie, Janssen-Cilag, AstraZeneca; Membership on an Entity's Board of Directors or Advisory Committees: AbbVie, Janssen-Cilag, AstraZeneca; Travel, accommodations, expenses: AbbVie, Janssen-Cilag, AstraZeneca. **AO:** No disclosures. **LL:** No disclosures. **PW:** No disclosures. **SO:** Consulting fees: AbbVie, Antengene, AstraZeneca, BeiGene, BMS, CSL Behring, Gilead, Merck, Novartis, Janssen, Roche, Takeda; Research funding: AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Janssen, Merck, Novartis, Pharmacyclics, Roche, Takeda; Honoraria: AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Janssen, Merck, Novartis, Roche, Takeda; Membership on an Entity's Board of Directors or Advisory Committees: AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Janssen, Merck, Novartis, Roche, Takeda outside the submitted work. **HC:** No disclosures. **RG:** Consulting fees: AbbVie, AstraZeneca, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Janssen, Merck, MSD, Novartis, Roche, Takeda, Honoraria: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Merck, MSD, Novartis, Roche, Takeda, Sandoz; Financial support for attending meetings or travel, or both: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Janssen, MSD, Novartis, Roche; Advisory board: AbbVie, AstraZeneca, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Janssen, Merck, MSD, Novartis, Roche. Takeda outside the submitted work. **MH:** No disclosures. **MT:** No disclosures. **MTr:** Consulting fees: AbbVie, Amgen, Janssen, Bristol Myers Squibb, Gilead Sciences, Incyte, MorphoSys, Novartis, Roche, Takeda; Honoraria: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Gilead Sciences, Incyte, Janssen, Roche, MorphoSys, Novartis, Portola, Takeda; Financial support for attending meetings or travel, or both: AbbVie, Bristol Myers Squibb, Gilead, Janssen, Roche, and Takeda; Advisory board: AbbVie, Bristol Myers Squibb, Incyte, Janssen, MorphoSys, Novartis, Portola, Roche, Takeda; Employment at Charles University General Hospital in Prague, outside the submitted work. **DB:** Funding from AbbVie, ArQule, Ascentage, AstraZeneca, BeiGene, DTRM, Genetech, Juno–Celgene–Bristol Myers Squibb, LOXO, MEI Pharma, Novartis, Pharmacyclics, TG Therapeutics; Consulting fees: AbbVie, Genentech, Pharmacyclics, Pfizer, TG Therapeutics, Verastem; Advisory board: AbbVie, Genentech, Novartis, Pharmacyclics, Pfizer, TG Therapeutics, Verastem; Leadership role with NCCN (panel member), InformCLL registry (steering committee; AbbVie), and Bloomlitars outcomes research panel (Pfizer), outside the submitted work. **IF:** Consultancy: All payments made to Sarah Cannon Research Institute, not to the physician AbbVie, AstraZeneca, BeiGene, Century Therapeutics, Genentech, Genmab, Hutchison MediPharma, Ikouda Therapeutics, InnoCare Pharma, Janssen, Kite Pharma, MorphoSys, Myeloid Therapeutics, Novartis, Nurix Therapeutics, Pharmacyclics, Roche, Secura Bio, Servier Pharmaceuticals, Takeda, TG Therapeutics, Verastem, Vincerx Pharma, Xencor, Research Grants: All payments made to Sarah Cannon Research Institute, not to the physician AbbVie, Acerta Pharma, Agios, AnaMar, AstraZeneca, BeiGene, Biopath, Bristol Myers Squibb, CALIBR, CALGB, Celgene, City of Hope National Medical Center, Constellation Pharmaceuticals, Curis, CTI Biopharma, Epizyme, Fate Therapeutics, Forma Therapeutics, Forty Seven, Genentech, Gilead Sciences, InnoCare Pharma, IGM Biosciences, Incyte, Infinity Pharmaceuticals, Janssen, Kite Pharma, Loxo, Merck, Millennium Pharmaceuticals, MorphoSys, Myeloid Therapeutics, Novartis, Nurix, Pfizer, Pharmacyclics, Portola Pharmaceuticals, Rhizen Pharmaceuticals, Roche, Seattle Genetics, Tessa Therapeutics, TCR2 Therapeutics, TG Therapeutics, Trillium Therapeutics, Triphase Research & Development Corp., Unum Therapeutics, Verastem, Zaenetty (ex: Membership on an Entity's Board of Directors or Advisory Committees: Vincerx. **SG:** No disclosures. **EV:** Research funding: Janssen Cilag Pty Ltd. **AT:** Consultancy: BeiGene, AstraZeneca, AbbVie, Janssen; Honoraria: BeiGene, AstraZeneca, AbbVie, Janssen; Speakers Bureau: BeiGene, AstraZeneca, AbbVie, Janssen; Travel, accommodations, expenses: BeiGene, AstraZeneca, AbbVie, Janssen. **SD:** Honoraria: Gilead Sciences, AbbVie, Janssen; Consultancy or advisory role: Gilead Sciences, AbbVie, Janssen. **GT:** No disclosures. **KL:** Grants/research support: AbbVie, Novartis, Takeda, Roche, Sandoz; Honoraria or speaker's bureau/personal fees: AbbVie, Novartis, Takeda, Roche, Sandoz, Celgene, Janssen, Amgen. **JG:** No disclosures. **AL:** No disclosures. **TT:** Employment: BeiGene. **VR:** Employment: BeiGene USA; Equity holder: BeiGene USA; Divested equity: BeiGene USA; Travel, accommodations, expenses: BeiGene USA. **YL:** Employment: BeiGene Ltd; Equity Holder: BeiGene Ltd; Travel, accommodations, expenses: BeiGene Ltd. **AS:** Employment: BeiGene. **JP:** Employment: BeiGene. **AC:** Employment: BeiGene; Equity holder: BeiGene. **CT:** Research funding: Janssen, AbbVie, BeiGene; Honoraria: Janssen, AbbVie, BeiGene, Loxo, AstraZeneca. **WJ:** Consultancy: Janssen, AstraZeneca, Mei Pharma, Lilly, Takeda, Roche, AbbVie, BeiGene; Research funding: AbbVie, Bayer, BeiGene, Celgene, Janssen, Roche, Takeda, TG Therapeutics, AstraZeneca, Mei Pharma, Lilly.

CORRESPONDENCE

Talha Munir
Haematological Malignancy Diagnostic Service
St James's Institute of Oncology
Leeds, UK
tmunir@nhs.net

ACKNOWLEDGMENTS

The authors thank the patients and their families, investigators, co-investigators, and the study teams at each of the participating centers. They also wish to recognize Carol Marinopoli, RN, Axel Glyko, Emily Mantovani, PharmD, Maria Salavert, and Harry Heraldo, all from BeiGene, for their contributions to data analysis and operational support. This study was sponsored by BeiGene Co. Ltd. Medical writing support was provided by Shivani Naidoo, PhD, and Heather Taft, PhD (Medical Expressions, LLC), and was supported by BeiGene Co. Ltd.

Presented at EHA 2023 Hybrid Congress; June 8-15, 2023; Frankfurt, Germany